Trial Profile
An Open-label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs VN B101 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors VitNovo
- 15 Oct 2018 Status changed from recruiting to completed.
- 03 Feb 2017 New trial record